Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.

摘要: Objective To determine the maximum tolerated dose (MTD) of cisplatin administered with piroxicam, antitumor activity and toxicity combined piroxicam in dogs oral malignant melanoma (OMM) squamous cell carcinoma (SCC), effects on pharmacokinetics tumors. Design Prospective nonrandomized clinical trial. Animals 25 dogs. Procedure Dogs were treated a combination (escalating 6 hours diuresis saline [0.9% NaCI] solution) (0.3 mg/kg 10.14 mg/lb], PO, q 24 h). The initial (50 mg/m2) was increased by 5 mg/m2 until MTD reached. Tumor stage size determined at 6-week intervals during treatment. receiving trial that alone. Results 11 OMM 9 SCC included when 50 mg/m2. remission occurred 2 OMM. most common abnormality observed renal toxicosis. Clearance alone not significantly different from piroxicam. Conclusions relevance Cisplatin had against SCC. level acceptable, although function must be monitored carefully.